Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4242 Campus Point Ct Ste 200
SAN DIEGO CA 92121
Tel: N/A
Website: www.herontx.com
IR: See website
<
Key People
Kevin C. Tang
Independent Chairman of the Board
Sean T. Ristine
Vice President - Human Resources
Barry D. Quart
President, Chief Executive Officer, Director
Robert E. Hoffman
Chief Financial Officer, Senior Vice President - Finance
David L. Szekeres
Senior Vice President, General Counsel, Business Development, Corporate Secretary
Anita Gupta
Senior Vice President - Medical Strategy and Government Affairs
Jesse Hollingsworth
Senior Vice President - Oncology Franchise
Michael Mathews
Senior Vice President - Pain Franchise
Thomas B. Ottoboni
Senior Vice President - Pharmaceutical and Preclinical Research and Development
Christopher M. Storgard
Senior Vice President - Clinical Development
   
Business Overview
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Financial Overview
For the fiscal year ended 31 December 2019, Heron Therapeutics Inc revenues increased 88% to $146M. Net loss increased 14% to $204.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects "Research and development - Balancing va increase of 17% to $148.2M (expense), Sales and marketing - Balancing value increase of 30% to $71.1M (expense).
Employees: 231 as of Feb 3, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $671.13M as of Dec 31, 2019
Annual revenue (TTM): $145.97M as of Dec 31, 2019
EBITDA (TTM): -$208.65M as of Dec 31, 2019
Net annual income (TTM): -$204.75M as of Dec 31, 2019
Free cash flow (TTM): -$131.73M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 90,374,284 as of Feb 3, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization